Renata Guimarães Ferreira Alvim

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Tecnologia

Unidade:

Coordenação dos Programas de Pós-Graduação de Engenharia

Departamento:

Programa de Engenharia Química/COPPE

ORCID:

não disponível no Lattes


Formação:

  • Universidade Federal do Rio de Janeiro

    Engenharia Química | Doutorado | 2019 - 2023

  • Universidade Federal do Rio de Janeiro

    ENGENHARIA de Processos Quimicos e Bioquimicos | Mestrado | 2017 - 2019

  • Universidade Federal do Rio de Janeiro

    Farmácia | Graduação | 2011 - 2016

  • Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro

    | Ensino Profissional de nível técnico | 2007 - 2011
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(100.00% artigos com DOI)

Titulo DOI Ano
Conformational stability of SARS-CoV-2 glycoprotein spike variants 10.1016/j.isci.2022.105696 2023
Antibody response and soluble mediator profile in the first six months following acute SARS-CoV-2 infection 10.1038/s41598-023-43263-y 2023
From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics 10.1016/j.bej.2022.108537 2022
Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum 10.3389/fimmu.2022.884760 2022
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study 10.3389/fimmu.2022.918896 2022
Process intensification for the production of yellow fever virus-like particles as potential recombinant vaccine antigen 10.1002/bit.27864 2021
Polyclonal F(ab?)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency 10.1016/j.isci.2021.103315 2021
Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform 10.1016/j.vaccine.2019.05.064 2019
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Development of a trivalent adjuvanted sub-unit vaccine candidate for Covid-19: From antigen expression to Ind-enabling CMC and preclinical studies 2024
Towards updatable, multivalent Covid vaccines: A platform process to produce trimeric spike protein of SARS-COV-2 variants expressed in HEK293 stable cell clones 2022
Perfusion process for the production of a new, VLP-based yellow fever vaccine candidate 2019
Production of Zika virus-like particles (VLPs) by perfusion processes 2019
Upstream process development for the production of zika and yellow fever virus-like particles (VLPs) 2018
Virus-like particles (VLPs) as a platform for the development of yellow fever and Zika virus vaccine candidate 2018
Development of perfusion processes for mAb production aiming at high cell densities sustained by low cell-specific perfusion rates 2018
PRODUCTION AND PURIFICATION OF ZIKA AND YELLOW FEVER VIRUS-LIKE PARTICLES (VLPS) EXPRESSED IN MAMMALIAN CELLS 2017
CHO SINGLE CELL SUBCLONING AND STABILITY OVER PROLONGED PASSAGING IN THE PRESENCE AND ABSENCE OF SELECTION PRESSURE 2017
Expression of Zika virus-like particles by different mammalian cell lines 2016
Publicações:
Minha Rede: